EPC-001 / Elpis Biopharma - LARVOL DELTA

Development of fully human anti-CD19 &CD22 bispecific tandem CAR-T for the treatment of resistant or relapsed B cell malignancies (AACR 2022) - "EPC-001 is a promising candidate that potentially prevents target escape by bivalent targeting of CD19 and CD22 simultaneously and overcome target escape with mono-specific engagement and CAR activation. EPC-001 has been advanced into clinic for proof of concept in investigator-initiated trial to treat CD19 CAR-T resistant/relapsed patients."

Late-breaking abstract • Oncology • CD22